Circassia Pharmaceuticals Plc European Launch of NIOX VERO® Nasal Mode (3936Q)
September 12 2017 - 1:00AM
UK Regulatory
TIDMCIR
RNS Number : 3936Q
Circassia Pharmaceuticals Plc
12 September 2017
Circassia Announces European Launch of NIOX VERO(R) Nasal Mode
for Screening of Primary Ciliary Dyskinesia
Oxford, UK - 12 September 2017: Circassia Pharmaceuticals plc
("Circassia" or "the Company"; LSE: CIR), a specialty
pharmaceutical company focused on respiratory disease, today
announces the European launch of the NIOX VERO(R) nasal application
for the screening of primary ciliary dyskinesia (PCD). Circassia
launched the application at the world's largest meeting of
respiratory professionals, the European Respiratory Society (ERS)
2017 International Congress in Milan, Italy.
At the ERS conference, Circassia hosted a NIOX(R) workshop at
which opinion leaders presented the use of nitric oxide as a
biomarker in the diagnosis and management of respiratory diseases.
The presentations focused on the clinical use of fractional exhaled
nitric oxide (FeNO) in asthma and the role of nasal nitric oxide
(nNO) in diagnosing PCD. Circassia also hosted an exhibition booth
at the conference, demonstrating the use of NIOX VERO(R) in both
these applications. In addition, Circassia presented data from its
recently completed study comparing nNO levels of known PCD subjects
with healthy subjects. This study, which enrolled approximately 160
subjects, demonstrated the ability of NIOX VERO(R) to differentiate
between the two groups. Following the completion of the study in H2
2016, Circassia finalised nNO measurement software for the NIOX
VERO(R) and associated nasal sampling kits, and recently completed
the European certification for this new application.
Steve Harris, Circassia's CEO, said: "We are delighted to launch
the new nasal application for NIOX VERO(R) to help European
specialists diagnose primary ciliary dyskinesia. This life-long
condition can lead to permanent lung damage and early diagnosis and
treatment is important. However, diagnosis can be difficult
currently, and we look forward to helping physicians improve the
process for patients with this challenging condition."
About primary ciliary dyskinesia
The prevalence of primary ciliary dyskinesia (PCD) is difficult
to estimate accurately, with studies suggesting it may affect
50,000 people in Europe. The condition is characterised by chronic
respiratory tract infections, and sufferers often have constant
nasal congestion and a chronic cough. Additionally, people with PCD
may have abnormally positioned internal organs, hearing problems
and infertility. Diagnosis can be complex and can include the use
of genetic testing and airway cilia biopsy. However, most people
with PCD have unusually low levels of nasal nitric oxide and
Circassia has adapted its NIOX VERO(R) system to accurately measure
this exhaled gas to assist the diagnosis of this genetic
condition.
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. Circassia sells its novel,
market-leading NIOX(R) asthma management products directly to
specialists in the United States, United Kingdom and Germany, and
in a wide range of other countries through its network of partners.
The Company recently established a collaboration with AstraZeneca
in the US in which it promotes the chronic obstructive pulmonary
disease (COPD) treatment Tudorza(R), and has the US commercial
rights to late-stage COPD product Duaklir(R).
Circassia's development pipeline includes a range of respiratory
medicines. The Company's lead asthma treatment targets substitution
of GSK's Flixotide(R) pMDI and was approved in the UK. Circassia is
also developing a direct substitute for Seretide(R) pMDI, and its
pipeline includes a number of inhaled medicines for COPD, including
single and combination dose products. For more information on
Circassia please visit www.circassia.com.
Contacts
Circassia
Steve Harris, Chief Executive Tel: +44 (0) 1865 405
Officer 560
Julien Cotta, Chief Financial
Officer
Rob Budge, Corporate Communications
JP Morgan Cazenove
James Mitford / James Deal Tel: +44 (0) 20 7742 4000
Numis Securities
Clare Terlouw / Freddie Tel: +44 (0) 20 7260 1000
Barnfield
FTI Consulting
Ben Atwell / Simon Conway Tel: +44 (0) 20 3727 1000
/ Mo Noonan
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLLBMTTMBTBBPR
(END) Dow Jones Newswires
September 12, 2017 02:00 ET (06:00 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024